Shares of Bajaj Healthcare Ltd climbed nearly 3% to ₹586.15 in Monday’s early trade following the company’s announcement of a strategic acquisition. As of April 8, the stock was trading higher by ₹16.85 or 2.96% compared to the previous close of ₹569.30 on the NSE. The day’s trading range stood between ₹581.45 and ₹597.90, with the company’s market capitalization at ₹1,854 crore.
In a regulatory filing post-market hours on April 7, the pharmaceutical company announced that it had acquired GenRx Pharmaceuticals Private Limited, a Thane-based firm, for a total cash consideration of ₹10.85 crore. The acquisition entails 100% equity control and is expected to be completed within the next 3 to 6 months, subject to FDA and other statutory approvals.
Founded in 2009, GenRx Pharmaceuticals is a WHO-GMP-certified manufacturer engaged in producing a wide range of pharmaceutical formulations, nutraceuticals, and natural healthcare products. Its manufacturing unit, located at MIDC Sinnar, Nashik, is equipped to produce various solid and semi-solid dosage forms, including tablets, capsules, external applications, cosmetic items, and nasal sprays.
The acquisition is part of Bajaj Healthcare’s broader strategic initiative to expand its formulation manufacturing capabilities and enhance its value chain. Commenting on the acquisition, Anil Jain, Managing Director of Bajaj Healthcare, stated,
“The acquisition of GenRx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth.”
He further added that the deal will provide a platform for long-term value creation and help the company cement its position in the pharmaceutical manufacturing ecosystem.
The company recently witnessed some leadership changes as well. Last week, Chief Financial Officer Dayashankar Patel resigned citing personal reasons, with no material concerns flagged in his exit statement.
From a financial standpoint, Bajaj Healthcare delivered a strong performance in Q3 FY25, reporting a net profit of ₹11.7 crore, reversing a net loss of ₹2.2 crore recorded in Q3 FY24. The company’s revenue from operations rose by 13.1% year-on-year to ₹122.8 crore from ₹108.6 crore in the year-ago period. The growth was led by robust demand for active pharmaceutical ingredients (APIs) and bulk drugs.
Its EBITDA for Q3 FY25 stood at ₹21.7 crore, up 10.7% from ₹19.6 crore a year earlier. However, the EBITDA margin came in slightly lower at 17.7%, compared to 18.1% in Q3 FY24.
Bajaj Healthcare is recognized for its global presence in the manufacturing of APIs, intermediates, and formulations, with exports to over 50 countries.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
